이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

iTeos Therapeutics 관리

관리 기준 확인 3/4

iTeos Therapeutics' CEO는 Michel Detheux, Aug2011 에 임명되었습니다 의 임기는 12.83 년입니다. 총 연간 보상은 $ 5.77M, 10% 로 구성됩니다. 10% 급여 및 90% 보너스(회사 주식 및 옵션 포함). 는 $ 317.89K 가치에 해당하는 회사 주식의 0.057% 직접 소유합니다. 317.89K. 경영진과 이사회의 평균 재임 기간은 각각 4 년과 4.3 년입니다.

주요 정보

Michel Detheux

최고 경영자

US$5.8m

총 보상

CEO 급여 비율	10.0%
CEO 임기	13.1yrs
CEO 소유권	0.06%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16

iTeos Therapeutics EPS misses by $0.11

Nov 12

CEO 보상 분석

Michel Detheux 의 보수는 iTeos Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-US$108m
Mar 31 2024	n/a	n/a	-US$135m
Dec 31 2023	US$6m	US$579k	-US$113m
Sep 30 2023	n/a	n/a	-US$62m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	US$12m
Dec 31 2022	US$11m	US$556k	US$97m
Sep 30 2022	n/a	n/a	US$261m
Jun 30 2022	n/a	n/a	US$330m
Mar 31 2022	n/a	n/a	US$298m
Dec 31 2021	US$6m	US$525k	US$215m
Sep 30 2021	n/a	n/a	US$15m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$50m
Dec 31 2020	US$17m	US$463k	-US$43m
Sep 30 2020	n/a	n/a	-US$35m
Jun 30 2020	n/a	n/a	-US$31m
Mar 31 2020	n/a	n/a	-US$28m
Dec 31 2019	US$2m	US$460k	-US$27m

보상 대 시장: Michel 의 총 보상 ($USD 5.77M )은 US 시장( $USD 2.46M ).

보상과 수익: Michel 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Michel Detheux (57 yo)

13.1yrs

테뉴어

US$5,767,774

보상

Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...

리더십 팀

이름	위치	테뉴어	보상	소유권
Michel Detheux	President	13.1yrs	US$5.77m	0.058% $ 216.1k
Matthew Gall	Chief Financial Officer	4.3yrs	US$2.72m	0.053% $ 197.5k
Matthew Call	Chief Operating Officer	5.1yrs	US$2.80m	0.26% $ 954.5k
Yvonne McGrath	Chief Scientific Officer	2.7yrs	데이터 없음	데이터 없음
Adi Osovsky	Executive Vice President of Legal	1.7yrs	데이터 없음	데이터 없음
Philippe Brantegem	Executive Vice President of Human Resources	4.7yrs	데이터 없음	데이터 없음
David Feltquate	Chief Medical Officer	less than a year	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: ITOS 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Michel Detheux	President	12.7yrs	US$5.77m	0.058% $ 216.1k
Ann Rhoads	Independent Director	4.3yrs	US$317.52k	0% $ 0
David Hallal	Independent Chairman of the Board	6.3yrs	US$416.42k	0% $ 0
Aaron Davis	Independent Director	4.5yrs	US$253.52k	0% $ 0
Timothy Van Hauwermeiren	Independent Director	6.3yrs	US$303.52k	0% $ 0
Matthew Vander Heiden	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Tony W. Ho	Independent Director	3.4yrs	US$305.02k	0% $ 0
Robert Iannone	Independent Director	3.4yrs	US$308.27k	0% $ 0
Gordon Freeman	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Benoit Van den Eynde	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Florent Ginhoux	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Roberta Zappasodi	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: ITOS 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

iTeos Therapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

iTeos Therapeutics, Inc. Appoints David Feltquate as Chief Medical Officer

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

Iteos Therapeutics, Inc. Announces Board Changes

Chief Operating Officer exercised options to buy US$531k worth of stock.

Recent updates

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics, Inc. Appoints David Feltquate as Chief Medical Officer

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

iTeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from Russell 2000 Value-Defensive Index

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

New minor risk - Shareholder dilution

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

iTeos Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $119.994271 million.

New major risk - Revenue size

Insufficient new directors

iTeos Therapeutics, Inc., Annual General Meeting, Jun 11, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

iTeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024

Iteos Therapeutics, Inc. Announces Board Changes

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.90 loss per share (vs US$0.028 profit in 3Q 2022)

New minor risk - Share price stability

Price target decreased by 11% to US$35.75

Second quarter 2023 earnings released: US$0.96 loss per share (vs US$0.16 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Consensus revenue estimates increase by 46%

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Price target decreased by 8.9% to US$40.27

Chief Operating Officer exercised options to buy US$531k worth of stock.

Investor sentiment deteriorates as stock falls 17%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

High number of new directors

iTeos Therapeutics, Inc. Announces Resignation of Matthew Roden from the Board

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

High number of new directors

Consensus revenue estimates fall by 23%

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

iTeos Therapeutics: Too Many Unknowns

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Independent Chairman of the Board notifies of intention to sell stock

Investor sentiment improved over the past week

High number of new directors

Price target decreased to US$46.20

Investor sentiment deteriorated over the past week

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Consensus revenue estimates increase by 30%

Price target increased to US$50.20

President notifies of intention to sell stock

iTeos Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

President exercised options and sold US$318k worth of stock

Price target increased to US$50.20

Consensus revenue estimates fall by 29%

Chief Medical Officer exercised options and sold US$111k worth of stock

Chief Scientific Officer exercised options and sold US$325k worth of stock

Chief Medical Officer exercised options and sold US$110k worth of stock

President notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$123k worth of stock

Chief Medical Officer exercised options and sold US$333k worth of stock

Chief Financial Officer recently sold US$232k worth of stock

Price target increased to US$50.00

Chief Medical Officer exercised options and sold US$106k worth of stock

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Chief Medical Officer exercised options and sold US$846k worth of stock

President notifies of intention to sell stock

Chief Financial Officer exercised options to buy US$381k worth of stock.

President notifies of intention to sell stock